HH
HSG Holding Ltd
13F filer · CIK 0001470766Reported May 15, 2026
13F portfolio value$1.24BU.S. long equity reported on 13F
Positions20Not reported new · Not reported closed
Net flow last quarterNot reportedBuys minus sells
Top 10 positions weight98.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q1 2026Reported May 15, 202620 positions | |||||
| $1.14B | 70.35% | 0.20% | Not reported | Q3 2018 | |
| $108M | 6.64% | Not reported | Not reported | Q3 2020 | |
| $100M | 6.18% | 1.74% | Not reported | Q2 2025 | |
| $65.4M | 4.03% | 0.18% | Not reported | Q1 2021 | |
| $55.2M | 3.41% | Not reported | Not reported | Q2 2025 | |
| $48.7M | 3.00% | Not reported | New | Q1 2026 | |
| $27.8M | 1.71% | 1.90% | Not reported | Q2 2021 | |
| $26.3M | 1.63% | Not reported | Not reported | Q1 2022 | |
| $14M | 0.86% | 1.46% | Not reported | Q1 2024 | |
| $7.82M | 0.48% | 0.13% | Not reported | Q2 2023 | |
| $7.54M | 0.47% | 8.73% | Not reported | Q2 2023 | |
| $6.33M | 0.39% | 0.75% | Not reported | Q3 2024 | |
| $6.2M | 0.38% | 0.12% | Not reported | Q3 2023 | |
| $2.89M | 0.18% | 0.12% | Not reported | Q2 2023 | |
| $2.03M | 0.13% | 2.27% | Not reported | Q3 2021 | |
| BBBRNSBarinthus Biotherapeutics plc. | $1.16M | 0.07% | 3.48% | Not reported | Q2 2022 |
| SSLAISOLAI Ltd | $627K | 0.04% | Not reported | Not reported | Q2 2023 |
| $544K | 0.03% | Not reported | New | Q1 2026 | |
| $73.1K | 0.00% | 0.65% | Not reported | Q2 2021 | |
| $62.4K | 0.00% | 0.85% | Not reported | Q2 2020 | |
| Q3 2025Reported Nov 14, 202519 positions | |||||
| $1.48B | 77.21% | 0.20% | -16.5% | Q3 2018 | |
| $125M | 6.52% | 0.18% | -30.0% | Q1 2021 | |
| $106M | 5.54% | Not reported | +1.0% | Q2 2025 | |
| $41.8M | 2.17% | 1.90% | Not reported | Q2 2021 | |
| $36.6M | 1.90% | 0.19% | Not reported | Q2 2023 | |
| $35.7M | 1.86% | Not reported | Not reported | Q3 2020 | |
| $20.7M | 1.08% | 0.31% | -81.8% | Q2 2025 | |
| $20.5M | 1.07% | Not reported | Not reported | Q1 2022 | |
| $13M | 0.68% | 1.62% | Not reported | Q1 2024 | |
| $9.09M | 0.47% | 0.71% | Not reported | Q3 2024 | |
| $7.05M | 0.37% | 45.31% | Not reported | Q2 2023 | |
| $6.95M | 0.36% | 0.15% | Not reported | Q2 2023 | |
| $4.61M | 0.24% | 0.15% | Not reported | Q3 2023 | |
| $4.5M | 0.23% | 0.12% | -86.2% | Q4 2013 | |
| $2.54M | 0.13% | 2.28% | Not reported | Q3 2021 | |
| BBBRNSBarinthus Biotherapeutics plc. | $1.96M | 0.10% | 3.48% | Not reported | Q2 2022 |
| SSLAISOLAI Ltd | $855K | 0.04% | Not reported | Not reported | Q2 2023 |
| $215K | 0.01% | 0.85% | Not reported | Q2 2020 | |
| $73.1K | 0.00% | 0.79% | Not reported | Q2 2021 | |
| Q2 2025Reported Aug 14, 202519 positions | |||||
| $1.42B | 73.32% | 0.24% | Not reported | Q3 2018 | |
| $131M | 6.74% | 0.26% | Not reported | Q1 2021 | |
| $113M | 5.83% | Not reported | New | Q2 2025 | |
| $78.2M | 4.03% | 1.69% | New | Q2 2025 | |
| $34.4M | 1.77% | Not reported | Not reported | Q3 2020 | |
| $34.3M | 1.77% | 0.87% | -3.8% | Q4 2013 | |
| $33.9M | 1.75% | 1.90% | Not reported | Q2 2021 | |
| $22.5M | 1.16% | Not reported | Not reported | Q1 2022 | |
| $22M | 1.13% | 0.19% | Not reported | Q2 2023 | |
| $14.4M | 0.74% | 1.77% | Not reported | Q1 2024 | |
| $10.6M | 0.55% | 0.71% | Not reported | Q3 2024 | |
| $8.6M | 0.44% | 45.31% | Not reported | Q2 2023 | |
| $5.52M | 0.28% | 0.15% | Not reported | Q3 2023 | |
| $3.37M | 0.17% | 0.15% | Not reported | Q2 2023 | |
| $2.62M | 0.13% | 2.28% | Not reported | Q3 2021 | |
| $1.35M | 0.07% | 1.03% | 0.0% | Q2 2021 | |
| BBBRNSBarinthus Biotherapeutics plc. | $1.32M | 0.07% | 3.52% | Not reported | Q2 2022 |
| SSLAISOLAI Ltd | $718K | 0.04% | Not reported | Not reported | Q2 2023 |
| $67K | 0.00% | 0.85% | Not reported | Q2 2020 | |
| Q1 2025Reported May 13, 202517 positions | |||||
| $1.37B | 80.18% | 0.24% | Not reported | Q3 2018 | |
| $108M | 6.32% | Not reported | Not reported | Q3 2020 | |
| $93.4M | 5.48% | 0.26% | Not reported | Q1 2021 | |
| $29.1M | 1.71% | Not reported | Not reported | Q1 2022 | |
| $27.8M | 1.63% | 1.90% | -74.2% | Q2 2021 | |
| $26.5M | 1.55% | 0.90% | Not reported | Q4 2013 | |
| $14M | 0.82% | 1.95% | Not reported | Q1 2024 | |
| $11M | 0.64% | 0.19% | Not reported | Q2 2023 | |
| $7.54M | 0.44% | 45.31% | 0.0% | Q2 2023 | |
| $6.33M | 0.37% | 0.71% | Not reported | Q3 2024 | |
| $6.2M | 0.36% | 0.15% | Not reported | Q3 2023 | |
| $2.89M | 0.17% | 0.15% | Not reported | Q2 2023 | |
| $2.03M | 0.12% | 2.28% | Not reported | Q3 2021 | |
| $1.46M | 0.09% | 1.03% | Not reported | Q2 2021 | |
| BBBRNSBarinthus Biotherapeutics plc. | $1.16M | 0.07% | 3.52% | Not reported | Q2 2022 |
| SSLAISOLAI Ltd | $627K | 0.04% | Not reported | Not reported | Q2 2023 |
| $62.4K | 0.00% | 0.85% | Not reported | Q2 2020 | |
Premium opens every quarter this fund has filed